Norges Bank bought a new stake in BioAtla, Inc. (NASDAQ:BCAB – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 389,100 shares of the company’s stock, valued at approximately $230,000.
Separately, XTX Topco Ltd increased its stake in BioAtla by 7.2% in the third quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock valued at $273,000 after purchasing an additional 10,384 shares during the last quarter. 77.23% of the stock is owned by institutional investors.
Analyst Ratings Changes
Separately, HC Wainwright restated a “neutral” rating on shares of BioAtla in a report on Monday, March 31st.
BioAtla Stock Performance
BCAB opened at $0.30 on Friday. BioAtla, Inc. has a one year low of $0.24 and a one year high of $3.53. The stock has a market capitalization of $17.68 million, a P/E ratio of -0.18 and a beta of 1.08. The business’s 50-day simple moving average is $0.36 and its 200-day simple moving average is $1.01.
BioAtla (NASDAQ:BCAB – Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.08. On average, equities research analysts forecast that BioAtla, Inc. will post -1.46 EPS for the current fiscal year.
BioAtla Profile
BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
See Also
- Five stocks we like better than BioAtla
- Using the MarketBeat Dividend Tax Calculator
- Robinhood Strategies Could Be a Game-Changer for Young Investors
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Are These 3 Retail Stocks Oversold or Really in Trouble?
- There Are Different Types of Stock To Invest In
- IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
Want to see what other hedge funds are holding BCAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioAtla, Inc. (NASDAQ:BCAB – Free Report).
Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with MarketBeat.com's FREE daily email newsletter.
